Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Hosp Palliat Care. 2014 Dec;31(8):867-76. doi: 10.1177/1049909113510058. Epub 2013 Nov 17.

Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.

Author information

1
Istituto Nazionale Tumori, IRCCS Fondazione Pascale, SSD Terapia Antalgica, Via Mariano Semmola, 80131 Naples, Italy arturocuomo@libero.it.
2
Istituto Nazionale Tumori, IRCCS Fondazione Pascale, SSD Terapia Antalgica, Via Mariano Semmola, 80131 Naples, Italy.
3
Cardiology Department, Fondazione Maugeri IRCCS Veruno (NO), Veruno, Italy.

Abstract

Combination opioid agonist/antagonist therapy has been shown to preserve bowel function in patients with chronic cancer pain. This retrospective study evaluated the efficacy and tolerability of prolonged-released fixed-dose oxycodone-naloxone (PR OXN) in consecutive outpatients with chronic cancer pain. Of 206 patients prescribed PR OXN (mean age 61.3 ± 12.9 years; 52.9% female), 31.5% were opioid naïve. PR OXN was associated with a significant decrease in pain score measured on a visual analogue scale over 28 days (P < .0001), without adverse effects on bowel function, nor change in laxative use. PR OXN efficacy and tolerability were similar in opioid-naïve and -experienced patients, and among age-stratified subgroups. No severe side effects occurred. In a real-life outpatient setting, PR OXN provided analgesia without bowel dysfunction in patients with chronic cancer pain.

KEYWORDS:

advanced cancer pain; chronic cancer pain; combination therapy; opioid-induced constipation; outpatients; oxycodone/naloxone

PMID:
24249829
DOI:
10.1177/1049909113510058
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center